- Home
- SGHT vs BMEA Comparison
SGHT vs BMEA Comparison
Compare SGHT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- BMEA
- Stock Information
- Founded
- SGHT 2011
- BMEA 2017
- Country
- SGHT United States
- BMEA United States
- Employees
- SGHT N/A
- BMEA N/A
- Industry
- SGHT Medical Specialities
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- BMEA Health Care
- Exchange
- SGHT Nasdaq
- BMEA Nasdaq
- Market Cap
- SGHT 140.1M
- BMEA 125.4M
- IPO Year
- SGHT 2021
- BMEA 2021
- Fundamental
- Price
- SGHT $2.25
- BMEA $2.16
- Analyst Decision
- SGHT Buy
- BMEA Buy
- Analyst Count
- SGHT 7
- BMEA 12
- Target Price
- SGHT $3.83
- BMEA $28.45
- AVG Volume (30 Days)
- SGHT 270.5K
- BMEA 667.0K
- Earning Date
- SGHT 03-05-2025
- BMEA 05-01-2025
- Dividend Yield
- SGHT N/A
- BMEA N/A
- EPS Growth
- SGHT N/A
- BMEA N/A
- EPS
- SGHT N/A
- BMEA N/A
- Revenue
- SGHT $79,866,000.00
- BMEA N/A
- Revenue This Year
- SGHT $3.09
- BMEA N/A
- Revenue Next Year
- SGHT $13.61
- BMEA N/A
- P/E Ratio
- SGHT N/A
- BMEA N/A
- Revenue Growth
- SGHT N/A
- BMEA N/A
- 52 Week Low
- SGHT $2.17
- BMEA $1.87
- 52 Week High
- SGHT $8.45
- BMEA $14.43
- Technical
- Relative Strength Index (RSI)
- SGHT 37.59
- BMEA 33.35
- Support Level
- SGHT $2.64
- BMEA $2.27
- Resistance Level
- SGHT $3.13
- BMEA $2.29
- Average True Range (ATR)
- SGHT 0.22
- BMEA 0.25
- MACD
- SGHT -0.05
- BMEA -0.02
- Stochastic Oscillator
- SGHT 6.38
- BMEA 24.05
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.